GSK Collaborate with CureVac to Develop Next Generation mRNA COVID-19 Vaccines

Shots:

• CureVac to receive $90.14M up front, $90.14M as milestones on the achievement of specific milestones. GSK will be the marketing authorization holder for the vaccine (Ex-Switzerland) and will have exclusive rights in all countries except Germany, Austria and Switzerland
• Additionally, GSK will support the manufacture of ~100M doses of CureVac’s first generation COVID-19 vaccine candidate CVnCoV in 2021
• The development program will begin imminently, with the target of introducing the vaccine in 2022, subject to regulatory approval

Click here ­to­ read full press release/ article | Ref: GSK | Image: The Guardian Nigeria